The use of 3D patient derived tumor organoids holds great potential for basic, translational, and potentially clinical research. The current gold standard methods used for high-throughput cancer therapy screening are mostly restricted to a single endpoint analysis and provide limited information about the type of therapy response.
Organoid Brightfield Identification-based Therapy Screening provides a semi-automated workflow in a fully controlled environment for cell seeding and live-cell imaging using the Tecan Spark® Cyto multimode plate reader using a high-throughput, 384-well microplate. Automated data-processing and machine learning was applied for label-free brightfield image analysis to monitor growth rates and track movement. Furthermore, OrBITS can delineate cytotoxic and cytostatic effects of various anticancer drugs via inclusion of fluorescent cell death markers. The OrBITS image analysis integrates easily with the Spark® Cyto system and offers high-quality, time-lapse videos, graphs and tables as data output.
Christophe Deben: Center for Oncological Research (CORE)